Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
FOLD 
Amicus Therapeutics Inc (FOLD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: FOLD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15.82
1 Year Target Price $15.82
| 8 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.92% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.92B USD | Price to earnings Ratio - | 1Y Target Price 15.82 |
Price to earnings Ratio - | 1Y Target Price 15.82 | ||
Volume (30-day avg) 12 | Beta 0.53 | 52 Weeks Range 5.51 - 12.65 | Updated Date 07/8/2025 |
52 Weeks Range 5.51 - 12.65 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -5.41% | Operating Margin (TTM) -6.35% |
Management Effectiveness
Return on Assets (TTM) 3.95% | Return on Equity (TTM) -18.12% |
Valuation
Trailing PE - | Forward PE 49.02 | Enterprise Value 2055875453 | Price to Sales(TTM) 3.53 |
Enterprise Value 2055875453 | Price to Sales(TTM) 3.53 | ||
Enterprise Value to Revenue 3.79 | Enterprise Value to EBITDA 38.34 | Shares Outstanding 307931008 | Shares Floating 263933805 |
Shares Outstanding 307931008 | Shares Floating 263933805 | ||
Percent Insiders 0.72 | Percent Institutions 102.81 |
Upturn AI SWOT
Amicus Therapeutics Inc
Company Overview
History and Background
Amicus Therapeutics, founded in 2002, is a biotechnology company focused on developing therapies for rare genetic diseases. It has evolved from a research-focused organization to a commercial enterprise with approved products.
Core Business Areas
- Rare Disease Therapeutics: Amicus develops and commercializes therapies for rare genetic diseases, focusing on protein folding and enzyme replacement therapies.
Leadership and Structure
John F. Crowley serves as Chairman and CEO. The company has a typical corporate structure with functional departments such as R&D, Commercial, and Finance.
Top Products and Market Share
Key Offerings
- Galafold (migalastat): Galafold is an oral chaperone therapy approved for Fabry disease patients with amenable mutations. It competes with enzyme replacement therapies. Global Galafold revenue in 2023 was approximately $417.3 million. Competitors: Sanofi (ENZYME), Takeda (TAK)
- Pombiliti + Opfolda: Pombiliti + Opfolda is a two-component therapy for late-onset Pompe disease. Competitors: Sanofi (ENZYME). First full year sales expected in 2024, analysts are expecting strong sales.
Market Dynamics
Industry Overview
The rare disease therapeutics market is growing rapidly due to increased awareness, orphan drug designations, and advancements in gene therapy and precision medicine.
Positioning
Amicus is a key player in the rare disease space, specializing in Fabry and Pompe diseases. Its competitive advantage lies in its oral chaperone therapy for Fabry and innovative two-component therapy for Pompe, offering alternatives to traditional enzyme replacement therapies.
Total Addressable Market (TAM)
The rare disease market is estimated to be hundreds of billions of dollars globally. Amicus is positioned to capture a significant share of the Fabry and Pompe disease segments, as well as future pipeline products.
Upturn SWOT Analysis
Strengths
- Approved and marketed products (Galafold, Pombiliti + Opfolda)
- Strong pipeline of rare disease therapies
- Focus on protein folding technology
- Experienced management team
- Orphan drug designations
Weaknesses
- Reliance on a limited number of products
- High R&D expenses
- Commercialization challenges in certain markets
- Patent protection vulnerabilities
Opportunities
- Expanding indications for existing products
- Acquiring or licensing new rare disease assets
- Entering new geographic markets
- Developing gene therapy programs
Threats
- Competition from larger pharmaceutical companies
- Pricing pressures and reimbursement challenges
- Clinical trial failures
- Regulatory hurdles
- Generic erosion of Galafold
Competitors and Market Share
Key Competitors
- SNY
- TAK
Competitive Landscape
Amicus's oral chaperone therapy provides a unique advantage in the Fabry disease market compared to enzyme replacement therapies. However, competitors like Sanofi and Takeda have larger sales/marketing force.
Major Acquisitions
Callidus Biopharma
- Year: 2017
- Acquisition Price (USD millions): 130
- Strategic Rationale: Expanded pipeline with Pompe disease and other lysosomal storage disorder programs.
Growth Trajectory and Initiatives
Historical Growth: Amicus has experienced significant revenue growth since the launch of Galafold.
Future Projections: Analysts project continued revenue growth, driven by Galafold and launch of Pombiliti + Opfolda, and potential pipeline progress. Profitability is expected within the next few years.
Recent Initiatives: Recent initiatives include expanding the Galafold label, commercializing Pombiliti + Opfolda, and advancing its gene therapy programs.
Summary
Amicus Therapeutics is a growing biopharmaceutical company focused on rare diseases. Galafold's strong sales, coupled with the recent launch of Pombiliti + Opfolda are helping. High R&D costs continue to weigh on profitability. The company will need to successfully navigate competition and execute its pipeline strategy to maintain its growth trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Amicus Therapeutics Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are based on available data and may not be precise. Future results are subject to various risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amicus Therapeutics Inc
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2007-05-31 | CEO, President & Director Mr. Bradley L. Campbell M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 499 | Website https://amicusrx.com |
Full time employees 499 | Website https://amicusrx.com | ||
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.